Evidence map›Paper›PMID 41996444›Full record

ArticlePloS one2026

Soluble ST2 as a biomarker for predicting severe adverse events among pediatric patients with Mycoplasma pneumoniae pneumonia.

Fangying Cheng, Tingting Li, Lei Zhang, Menghua Xu, Luxi Chen, Zhicheng Ye, Jin Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fangying ChengDepartment of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Tingting LiDepartment of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Lei ZhangDepartment of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Menghua XuDepartment of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Luxi ChenDepartment of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Zhicheng YeDepartment of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.ORCID https://orcid.org/0009-0009-6967-6969
Jin XuDepartment of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimMycoplasma pneumoniae (MP) is a leading cause of pneumonia in children. Early identification of patients at high risk is critical for improving outcomes. This study aimed to evaluate the association of soluble ST2 (sST2) with in-hospital adverse events in pediatric MP pneumonia (MPP).

methodsWe retrospectively analyzed 147 children with MPP admitted to the Children's Hospital of Fudan University, Shanghai, China, between 01/04/2023 and 31/05/2024. Demographic, clinical, and laboratory data were collected, including sST2, inflammatory markers (CRP, PCT, IL-6), and blood cell counts. Severe adverse events were defined as in-hospital death, ICU admission, diagnosis of sepsis or use of extracorporeal membrane oxygenation.

resultsTwelve patients experienced severe adverse events and had significantly higher sST2 levels. ROC analysis showed that sST2 predicted severe adverse events (AUC = 0.944, 95% CI 0.894-0.975, P < 0.001), with an optimal cut-off of 114.18 ng/mL (sensitivity 91.7%, specificity 94.8%). The association remained significant after adjusting for age, sex, PCT, and IL-6. In addition, admission sST2 levels were significantly higher in severe MPP cases, those with co-infections and those with pulmonary complications and/or extrapulmonary complications during hospitalization. sST2 correlated positively with hospital length of stay and preadmission fever duration. They also correlated positively with neutrophil counts, neutrophil to lymphocyte ratio, PCT, CRP and IL-6 but negatively with lymphocyte counts. Conclusions. sST2 was associated with in-hospital adverse events and it showed better performance in predicting severe adverse events than other inflammatory biomarkers. The potential of sST2 as a prognostic biomarker for MPP warrants further investigation.

Indexed as

Interleukin-1 Receptor-Like 1 ProteinMycoplasma pneumoniaePneumonia, MycoplasmaBiomarkersChildChild, PreschoolChinaFemaleHumansInfantInterleukin-6MalePrognosisRetrospective StudiesROC CurveBiomarkersIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 ProteinInterleukin-6

Identifiers

PMID41996444
PMCPMC13089705

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.